Mechanism of Action and Clinical Rationale for Immunotherapy in Bladder Cancer

In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the mechanism of action and clinical rationale for the use of immune checkpoint inhibitors in patients with bladder cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 3.89 MB
Released: February 12, 2018

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Produced in collaboration with
Educational grant provided by:
Merck & Co., Inc.
Seattle Genetics
Astellas

Related Content

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v1.2020, from CCO

Released: October 16, 2020

Download this slideset from Clinical Care Options, to see the latest data on first-line immunotherapy treatment options for patients with advanced HCC.

Ghassan K. Abou-Alfa, MD, MBA Released: October 14, 2020

Download this slideset from Clinical Care Options, to see the latest data on immunotherapy treatment options for patients with early HCC.

Peter R. Galle, MD, PhD Released: October 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue